These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 24191958)

  • 1. PARP inhibitors: an interesting pathway also for non-small cell lung cancer?
    Levra MG; Olaussen KA; Novello S; Soria JC
    Curr Pharm Des; 2014; 20(24):3875-82. PubMed ID: 24191958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer.
    Paul I; Savage KI; Blayney JK; Lamers E; Gately K; Kerr K; Sheaff M; Arthur K; Richard DJ; Hamilton PW; James JA; O'Byrne KJ; Harkin DP; Quinn JE; Fennell DA
    J Pathol; 2011 Aug; 224(4):564-74. PubMed ID: 21706479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs.
    Olaussen KA; Adam J; Vanhecke E; Vielh P; Pirker R; Friboulet L; Popper H; Robin A; Commo F; Thomale J; Kayitalire L; Filipits M; Le Chevalier T; André F; Brambilla E; Soria JC
    Lung Cancer; 2013 May; 80(2):216-22. PubMed ID: 23410825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer.
    Michels J; Vitale I; Senovilla L; Enot DP; Garcia P; Lissa D; Olaussen KA; Brenner C; Soria JC; Castedo M; Kroemer G
    Cell Cycle; 2013 Mar; 12(6):877-83. PubMed ID: 23428903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [DNA repair pathways and non-small cell lung cancer: clinical perspectives].
    Olaussen KA; Planchard D; Adam J; Soria JC
    Bull Cancer; 2011 Mar; 98(3):305-22. PubMed ID: 21459711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells.
    Senhaji Mouhri Z; Goodfellow E; Jean-Claude B
    BMC Cancer; 2017 Aug; 17(1):540. PubMed ID: 28800752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of PPP2R2A inhibits homologous recombination DNA repair and predicts tumor sensitivity to PARP inhibition.
    Kalev P; Simicek M; Vazquez I; Munck S; Chen L; Soin T; Danda N; Chen W; Sablina A
    Cancer Res; 2012 Dec; 72(24):6414-24. PubMed ID: 23087057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcriptomics reveals
    Stolzenburg LR; Ainsworth B; Riley-Gillis B; Pakozdi T; Ammar A; Ellis PA; Wilsbacher JL; Ramathal CY
    Oncotarget; 2022; 13():1-12. PubMed ID: 35018214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective.
    Sandhu SK; Yap TA; de Bono JS
    Eur J Cancer; 2010 Jan; 46(1):9-20. PubMed ID: 19926276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poly(ADP-ribose)polymerase (PARP) inhibitors: from bench to bedside.
    Plummer R
    Clin Oncol (R Coll Radiol); 2014 May; 26(5):250-6. PubMed ID: 24602564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic effect of olaparib with combination of cisplatin on PTEN-deficient lung cancer cells.
    Minami D; Takigawa N; Takeda H; Takata M; Ochi N; Ichihara E; Hisamoto A; Hotta K; Tanimoto M; Kiura K
    Mol Cancer Res; 2013 Feb; 11(2):140-8. PubMed ID: 23239809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PARP inhibitors in small cell lung cancer: The underlying mechanisms and clinical implications.
    Wang X; Zeng X; Li D; Zhu C; Guo X; Feng L; Yu Z
    Biomed Pharmacother; 2022 Sep; 153():113458. PubMed ID: 36076571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy.
    Heitz F; Harter P; Ewald-Riegler N; Papsdorf M; Kommoss S; du Bois A
    Expert Rev Anticancer Ther; 2010 Jul; 10(7):1125-36. PubMed ID: 20645701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poly(ADP-ribose) polymerase activity and inhibition in cancer.
    Dulaney C; Marcrom S; Stanley J; Yang ES
    Semin Cell Dev Biol; 2017 Mar; 63():144-153. PubMed ID: 28087320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic.
    Yap TA; Sandhu SK; Carden CP; de Bono JS
    CA Cancer J Clin; 2011; 61(1):31-49. PubMed ID: 21205831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.
    Du Y; Yamaguchi H; Wei Y; Hsu JL; Wang HL; Hsu YH; Lin WC; Yu WH; Leonard PG; Lee GR; Chen MK; Nakai K; Hsu MC; Chen CT; Sun Y; Wu Y; Chang WC; Huang WC; Liu CL; Chang YC; Chen CH; Park M; Jones P; Hortobagyi GN; Hung MC
    Nat Med; 2016 Feb; 22(2):194-201. PubMed ID: 26779812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Small Compound KJ-28d Enhances the Sensitivity of Non-Small Cell Lung Cancer to Radio- and Chemotherapy.
    Ryu H; Kim HJ; Song JY; Hwang SG; Kim JS; Kim J; Bui THN; Choi HK; Ahn J
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31795418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repositioning PARP inhibitors in the treatment of thoracic malignancies.
    Passiglia F; Reale ML; Cetoretta V; Parlagreco E; Jacobs F; Listì A; Righi L; Bironzo P; Novello S; Scagliotti GV
    Cancer Treat Rev; 2021 Sep; 99():102256. PubMed ID: 34261032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PARP Inhibitors: The Cornerstone of DNA Repair-Targeted Therapies.
    del Rivero J; Kohn EC
    Oncology (Williston Park); 2017 Apr; 31(4):265-73. PubMed ID: 28412778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in PARP inhibitors for the treatment of breast cancer.
    Dizdar O; Arslan C; Altundag K
    Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.